Published in Hepatitis Weekly, July 24th, 1995
A chronic liver disease of unknown etiology, CAH-A is believed to have an autoimmune pathogenesis. The disease slowly progresses until hepatic failure and the development of portal hypertension, after which either death of liver transplantation occur. At present, the only widely recognized therapy is the administration of glucocorticoids. Glucocorticoids have both anti-inflammatory and immunosuppressive actions, and because of the psychiatric, osteoporotic and weight-enhancing actions of steroids, many patients are unable to tolerate such therapy. Other such...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.